GB201617758D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB201617758D0
GB201617758D0 GBGB1617758.6A GB201617758A GB201617758D0 GB 201617758 D0 GB201617758 D0 GB 201617758D0 GB 201617758 A GB201617758 A GB 201617758A GB 201617758 D0 GB201617758 D0 GB 201617758D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1617758.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Priority to GBGB1617758.6A priority Critical patent/GB201617758D0/en
Publication of GB201617758D0 publication Critical patent/GB201617758D0/en
Priority to KR1020197014463A priority patent/KR20190069529A/ko
Priority to RU2019115115A priority patent/RU2019115115A/ru
Priority to EP22157226.6A priority patent/EP4026832A1/en
Priority to SG11201903456WA priority patent/SG11201903456WA/en
Priority to MX2019004450A priority patent/MX2019004450A/es
Priority to CN201780077139.8A priority patent/CN110088096A/zh
Priority to EP17790829.0A priority patent/EP3529241B1/en
Priority to AU2017346516A priority patent/AU2017346516B2/en
Priority to ES17790829T priority patent/ES2914284T3/es
Priority to US16/343,917 priority patent/US10766903B2/en
Priority to JP2019520996A priority patent/JP7073359B2/ja
Priority to PCT/GB2017/053175 priority patent/WO2018073602A1/en
Priority to DK17790829.0T priority patent/DK3529241T3/da
Priority to CA3040805A priority patent/CA3040805A1/en
Priority to BR112019007977A priority patent/BR112019007977A2/pt
Priority to MX2021012589A priority patent/MX2021012589A/es
Priority to IL266146A priority patent/IL266146A/en
Priority to JP2022077871A priority patent/JP2022106953A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1617758.6A 2016-10-20 2016-10-20 Pharmaceutical compounds Ceased GB201617758D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1617758.6A GB201617758D0 (en) 2016-10-20 2016-10-20 Pharmaceutical compounds
BR112019007977A BR112019007977A2 (pt) 2016-10-20 2017-10-20 composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
AU2017346516A AU2017346516B2 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
US16/343,917 US10766903B2 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
EP22157226.6A EP4026832A1 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
SG11201903456WA SG11201903456WA (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
MX2019004450A MX2019004450A (es) 2016-10-20 2017-10-20 Derivados de piperidina como inhibidores de proteasa especifica de ubiquitina 7.
CN201780077139.8A CN110088096A (zh) 2016-10-20 2017-10-20 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物
EP17790829.0A EP3529241B1 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
KR1020197014463A KR20190069529A (ko) 2016-10-20 2017-10-20 유비퀴틴 특이적 프로테아제 7의 억제제로서 피페리딘 유도체
ES17790829T ES2914284T3 (es) 2016-10-20 2017-10-20 Derivados de piperidina como inhibidores de la proteasa específica de la ubiquitina 7
RU2019115115A RU2019115115A (ru) 2016-10-20 2017-10-20 Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2019520996A JP7073359B2 (ja) 2016-10-20 2017-10-20 ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
PCT/GB2017/053175 WO2018073602A1 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
DK17790829.0T DK3529241T3 (da) 2016-10-20 2017-10-20 Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
CA3040805A CA3040805A1 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7
MX2021012589A MX2021012589A (es) 2016-10-20 2019-04-16 Derivados de piperidina como inhibidores de proteasa especifica de ubiquitina 7.
IL266146A IL266146A (en) 2016-10-20 2019-04-18 Pepridine derivatives as protease 7-specific ubiquitin inhibitors
JP2022077871A JP2022106953A (ja) 2016-10-20 2022-05-11 ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1617758.6A GB201617758D0 (en) 2016-10-20 2016-10-20 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB201617758D0 true GB201617758D0 (en) 2016-12-07

Family

ID=57738053

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1617758.6A Ceased GB201617758D0 (en) 2016-10-20 2016-10-20 Pharmaceutical compounds

Country Status (16)

Country Link
US (1) US10766903B2 (cg-RX-API-DMAC7.html)
EP (2) EP3529241B1 (cg-RX-API-DMAC7.html)
JP (2) JP7073359B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190069529A (cg-RX-API-DMAC7.html)
CN (1) CN110088096A (cg-RX-API-DMAC7.html)
AU (1) AU2017346516B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019007977A2 (cg-RX-API-DMAC7.html)
CA (1) CA3040805A1 (cg-RX-API-DMAC7.html)
DK (1) DK3529241T3 (cg-RX-API-DMAC7.html)
ES (1) ES2914284T3 (cg-RX-API-DMAC7.html)
GB (1) GB201617758D0 (cg-RX-API-DMAC7.html)
IL (1) IL266146A (cg-RX-API-DMAC7.html)
MX (2) MX2019004450A (cg-RX-API-DMAC7.html)
RU (1) RU2019115115A (cg-RX-API-DMAC7.html)
SG (1) SG11201903456WA (cg-RX-API-DMAC7.html)
WO (1) WO2018073602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
JP7402792B2 (ja) * 2017-09-26 2023-12-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
JP7508449B2 (ja) * 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ７の阻害
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
CN117050086A (zh) * 2019-04-11 2023-11-14 四川科伦博泰生物医药股份有限公司 含有并环基团的嘧啶酮并吡唑类化合物、其制备方法及用途
CN113423709B (zh) * 2019-04-11 2024-02-09 四川科伦博泰生物医药股份有限公司 三嗪酮并咪唑类化合物及其医药用途
EP3965749A4 (en) * 2019-05-06 2023-06-21 Valo Health, Inc. INHIBITION OF USP19
CN118108744A (zh) * 2020-01-08 2024-05-31 四川科伦博泰生物医药股份有限公司 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
CA3167473A1 (en) 2020-02-28 2021-09-02 Immunologik Gmbh Inhibitors of human deubiquitinases for the treatment of coronaviral infections
CN113801135B (zh) * 2020-06-15 2025-06-24 四川科伦博泰生物医药股份有限公司 噻吩并吡唑类化合物，包含其的药物组合物及其用途
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用
CN114478437A (zh) * 2020-11-11 2022-05-13 山东特珐曼药业有限公司 一种制备n-甲基-2-吡咯烷乙胺或其盐的方法
CN113336714A (zh) * 2021-06-25 2021-09-03 山东大学 一种化合物及其制备方法和应用
WO2022272133A2 (en) * 2021-06-25 2022-12-29 Stablix, Inc. Protein stabilizing compounds containing usp7 ligands
CN118401507A (zh) * 2021-07-20 2024-07-26 丹娜法伯癌症研究院 靶向泛素特异性蛋白酶7（usp7）的抑制剂
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
CN114507278B (zh) * 2022-01-27 2023-04-25 苏州大学 一种犹素探针UFM1-Lys-TAMRA及其合成方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
AU2003301095A1 (en) 2002-12-23 2004-07-22 Merck And Co., Inc. 4(spiropiperidinyl)methyl substituted pyrrolidines as modulators of chemokine receptor activity
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7943636B2 (en) * 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2009502801A (ja) 2005-07-22 2009-01-29 サネシス ファーマシューティカルズ， インコーポレイテッド Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン
EP1749822B1 (en) 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
US20100121048A1 (en) * 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
CA2666406A1 (en) * 2006-10-16 2008-04-24 Gruenenthal Gmbh Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators
US7875613B2 (en) 2006-10-30 2011-01-25 Hybrigenics Sa Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
FR2911138B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN101896473B (zh) 2007-12-11 2012-07-25 霍夫曼-拉罗奇有限公司 硬脂酰基辅酶a去饱和酶抑制剂
ES2531398T3 (es) * 2008-02-22 2015-03-13 Msd Kk Nuevos derivados de aminopiridina que tienen una acción inhibidora selectiva de Aurora A
CN102099339A (zh) * 2008-07-18 2011-06-15 武田药品工业株式会社 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途
CA2732628A1 (en) 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Therapeutic agents
WO2010020556A1 (en) * 2008-08-22 2010-02-25 Evotec Neurosciences Gmbh New bradykinin b1 antagonists
EP2208725A1 (en) 2009-01-13 2010-07-21 Hybrigenics S.A. Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications
US8680139B2 (en) 2009-04-01 2014-03-25 Progenra Anti-neoplastic compounds, compositions and methods
EP2515657A4 (en) 2009-12-21 2013-07-03 Merck Sharp & Dohme Tyrosine kinase inhibitor
EP2357176A1 (en) 2010-01-15 2011-08-17 Hybrigenics S.A. Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
JP5765342B2 (ja) * 2010-08-10 2015-08-19 アステラス製薬株式会社 へテロ環化合物
JP2012072067A (ja) * 2010-09-28 2012-04-12 Astellas Pharma Inc 含窒素芳香族へテロ環化合物
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
UA115133C2 (uk) * 2011-10-07 2017-09-25 Такеда Фармасьютікал Компані Лімітед Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань
WO2013080141A1 (en) * 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
WO2014045101A1 (en) * 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AP2016009020A0 (en) * 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015046193A1 (ja) * 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
RU2021102805A (ru) * 2014-12-05 2021-02-12 Эррэй Биофарма Инк. 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
US9932351B2 (en) * 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
US9938300B2 (en) * 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3271333B1 (en) 2015-03-20 2022-01-12 F. Hoffmann-La Roche AG Usp7 inhibitor compounds and methods of use
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
ES3033182T3 (en) * 2016-09-20 2025-07-31 Dana Farber Cancer Inst Inc Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators

Also Published As

Publication number Publication date
CN110088096A (zh) 2019-08-02
MX2021012589A (es) 2021-11-12
EP4026832A1 (en) 2022-07-13
ES2914284T3 (es) 2022-06-08
EP3529241B1 (en) 2022-04-06
SG11201903456WA (en) 2019-05-30
AU2017346516A1 (en) 2019-05-02
US20190256518A1 (en) 2019-08-22
CA3040805A1 (en) 2018-04-26
IL266146A (en) 2019-06-30
US10766903B2 (en) 2020-09-08
DK3529241T3 (da) 2022-07-11
JP2019535664A (ja) 2019-12-12
KR20190069529A (ko) 2019-06-19
JP2022106953A (ja) 2022-07-20
EP3529241A1 (en) 2019-08-28
RU2019115115A3 (cg-RX-API-DMAC7.html) 2020-11-24
RU2019115115A (ru) 2020-11-24
MX2019004450A (es) 2019-08-05
WO2018073602A1 (en) 2018-04-26
JP7073359B2 (ja) 2022-05-23
AU2017346516B2 (en) 2021-10-14
BR112019007977A2 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
IL266017A (en) Pharmaceutical compounds
IL258213A (en) Pharmaceutical compounds
GB201612092D0 (en) Pharmaceutical compounds
ZA201900540B (en) Pharmaceutical compounds
GB201617758D0 (en) Pharmaceutical compounds
GB201504675D0 (en) Pharmaceutical compounds
GB201506658D0 (en) Pharmaceutical compounds
GB201519352D0 (en) Pharmaceutical compounds
ES3050708T3 (en) Pharmaceutical compounds
GB201506660D0 (en) Pharmaceutical compounds
GB201617454D0 (en) Pharmaceutical compounds
IL258246A (en) Pharmaceutical compounds
GB201704714D0 (en) Pharmaceutical compounds
GB201617627D0 (en) Pharmaceutical compounds
GB201612095D0 (en) Pharmaceutical compounds
GB201704965D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
GB201706806D0 (en) Pharmaceutical compounds
GB201711704D0 (en) Pharmaceutical compounds
HRP20220427T8 (hr) Farmaceutski spojevi
GB201704966D0 (en) Pharmaceutical compounds
GB201617871D0 (en) Pharmaceutical compounds
GB201615916D0 (en) Pharmaceutical compound

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)